A novel monoclonal antibody targets mucin1 and attenuates growth in pancreatic cancer model

International Journal of Molecular Sciences

Volumn 19, Issue 7, 2018, Pages

  Wu, Guang ^a   Maharjan, Sony ^a   Kim, Dongbum ^a   Kim, Jung Nam ^a   Park, Byoung Kwon ^a   Koh, Heeju ^b   Moon, Kyungduk ^b   Lee, Younghee ^c   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Peptron Inc   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Antibody therapeutics; Monoclonal antibody; Mucin1; Pancreatic cancer; Targeting

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; FLUORESCENT DYE; IMMUNOGLOBULIN G; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MUCIN 1; MUCIN 1 ANTIBODY; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MUC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PANCREAS TUMOR; PHOSPHORYLATION; TREATMENT OUTCOME; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MUCIN-1; PANCREATIC NEOPLASMS; PHOSPHORYLATION; TREATMENT OUTCOME; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85049886878     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19072004     Document Type: Article

References (31)

1. Gunturu, K.S.; Rossi, G.R.; Saif, M.W. Immunotherapy updates in pancreatic cancer: Are we there yet? Ther. Adv. Med. Oncol. 2013, 5, 81–89.
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017, 67, 7–30.
3. Bilimoria, K.Y.; Bentrem, D.J.; Ko, C.Y.; Ritchey, J.; Stewart, A.K.; Winchester, D.P.; Talamonti, M.S. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: Report from the National Cancer Database. Cancer 2007, 110, 738–744.
4. Torres, M.P.; Chakraborty, S.; Souchek, J.; Batra, S.K. Mucin-based targeted pancreatic cancer therapy. Curr. Pharm. Des. 2012, 18, 2472–2481.
5. Kaur, S.; Kumar, S.; Momi, N.; Sasson, A.R.; Batra, S.K. Mucins in pancreatic cancer and its microenvironment. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 607–620.
6. Kufe, D.W. MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches. Oncogene 2013, 32, 1073–1081.
7. Kufe, D.W. Mucins in cancer: Function, prognosis and therapy. Nat. Rev. Cancer 2009, 9, 874–885.
8. Moniaux, N.; Andrianifahanana, M.; Brand, R.E.; Batra, S.K. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br. J. Cancer 2004, 91, 1633–1638.
9. Schroeder, J.A.; Masri, A.A.; Adriance, M.C.; Tessier, J.C.; Kotlarczyk, K.L.; Thompson, M.C.; Gendler, S.J. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004, 23, 5739–5747.
10. Satoh, S.; Hinoda, Y.; Hayashi, T.; Burdick, M.D.; Imai, K.; Hollingsworth, M.A. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int. J. Cancer 2000, 88, 507–518.
11. Kohlgraf, K.G.; Gawron, A.J.; Higashi, M.; Meza, J.L.; Burdick, M.D.; Kitajima, S.; Kelly, D.L.; Caffrey, T.C.; Hollingsworth, M.A. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 2003, 63, 5011–5020.
12. Nath, S.; Daneshvar, K.; Roy, L.D.; Grover, P.; Kidiyoor, A.; Mosley, L.; Sahraei, M.; Mukherjee, P. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis 2013, 2, e51.
13. Nagata, K.; Horinouchi, M.; Saitou, M.; Higashi, M.; Nomoto, M.; Goto, M.; Yonezawa, S. Mucin expression profile in pancreatic cancer and the precursor lesions. J. Hepato-Biliary Pancreat. Surg. 2007, 14, 243–254.
14. Yonezawa, S.; Higashi, M.; Yamada, N.; Yokoyama, S.; Goto, M. Significance of mucin expression in pancreatobiliary neoplasms. J. Hepato-Biliary Pancreat. Sci. 2010, 17, 108–124.
15. Merlin, J.; Stechly, L.; de Beauce, S.; Monte, D.; Leteurtre, E.; van Seuningen, I.; Huet, G.; Pigny, P. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 2011, 30, 2514–2525.
16. Tobita, K.; Kijima, H.; Dowaki, S.; Kashiwagi, H.; Ohtani, Y.; Oida, Y.; Yamazaki, H.; Nakamura, M.; Ueyama, Y.; Tanaka, M.; et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int. J. Mol. Med. 2003, 11, 305–309.
17. Bruns, C.J.; Solorzano, C.C.; Harbison, M.T.; Ozawa, S.; Tsan, R.; Fan, D.; Abbruzzese, J.; Traxler, P.; Buchdunger, E.; Radinsky, R.; et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000, 60, 2926–2935.
18. Lurje, G.; Lenz, H.J. EGFR signaling and drug discovery. Oncology 2009, 77, 400–410.
19. Hisatsune, A.; Nakayama, H.; Kawasaki, M.; Horie, I.; Miyata, T.; Isohama, Y.; Kim, K.C.; Katsuki, H. Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells. Biochem. Biophys. Res. Commun. 2011, 405, 377–381.
20. Wu, G.; Kim, D.; Kim, J.N.; Park, S.; Maharjan, S.; Koh, H.; Moon, K.; Lee, Y.; Kwon, H.J. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer. Theranostics 2018, 8, 78–91.
21. Schroeder, J.A.; Thompson, M.C.; Gardner, M.M.; Gendler, S.J. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J. Biol. Chem. 2001, 276, 13057–13064.
22. Nai, Q.; Luo, H.; Zhang, P.; Hossain, M.A.; Gu, P.; Sidhom, I.W.; Mathew, T.; Islam, M.; Yousif, A.M.; Sen, S. How early can pancreatic cancer be recognized? A case report and review of the literature. Case Rep. Oncol. 2015, 8, 46–49.
23. Cartwright, T.; Richards, D.A.; Boehm, K.A. Cancer of the pancreas: Are we making progress? A review of studies in the us oncology research network. Cancer Control 2008, 15, 308–313.
24. Lockhart, A.C.; Rothenberg, M.L.; Berlin, J.D. Treatment for pancreatic cancer: Current therapy and continued progress. Gastroenterology 2005, 128, 1642–1654.
25. Nath, S.; Mukherjee, P. MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med. 2014, 20, 332–342.
26. Oei, A.L.; Moreno, M.; Verheijen, R.H.; Sweep, F.C.; Thomas, C.M.; Massuger, L.F.; von Mensdorff-Pouilly, S. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int. J. Cancer 2008, 123, 1848–1853.
27. Wang, L.; Chen, H.; Pourgholami, M.H.; Beretov, J.; Hao, J.; Chao, H.; Perkins, A.C.; Kearsley, J.H.; Li, Y. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites and prolong survival in an in vivo ovarian cancer model. PLoS ONE 2011, 6, e24405.
28. Danielczyk, A.; Stahn, R.; Faulstich, D.; Loffler, A.; Marten, A.; Karsten, U.; Goletz, S. Pankomab: A potent new generation anti-tumour MUC1 antibody. Cancer Immunol. Immunother. 2006, 55, 1337–1347.
29. Maharjan, S.; Park, B.K.; Lee, S.I.; Lim, Y.; Lee, K.; Kwon, H.J. Gomisin G inhibits the growth of triple-negative breast cancer cells by suppressing AKT phosphorylation and decreasing cyclin D1. Biomol. Ther. (Seoul) 2018, 26, 322–327.
30. Kwon, S.; Choi, K.C.; Kim, Y.E.; Ha, Y.W.; Kim, D.; Park, B.K.; Wu, G.; Kim, D.S.; Lee, Y.; Kwon, H.J. Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014, 74, 3844–3856.
31. Wu, G.; Kim, D.; Park, B.K.; Park, S.; Ha, J.H.; Kim, T.H.; Gautam, A.; Kim, J.N.; Lee, S.I.; Park, H.B.; et al. Anti-metastatic effect of the TM4SF5-specific peptide vaccine and humanized monoclonal antibody on colon cancer in a mouse lung metastasis model. Oncotarget 2016, 7, 79170–79186.